Methergin (Methylergometrine Maleate)

Methylergometrine acts as a partial agonist at serotonin 5‑HT2 receptors and alpha‑adrenergic receptors on uterine smooth muscle. This dual activation raises intracellular calcium levels, producing sustained myometrial contraction that compresses uterine blood vessels and reduces postpartum bleeding.

The specific dose of Methergin is determined by the prescribing clinician based on the clinical situation, route of administration, and patient characteristics. Healthcare professionals follow local guidelines and product labeling to select an appropriate dose for each individual case.

Methergin is classified as pregnancy category X because it can cause uterine hyperstimulation and fetal harm. It is contraindicated during pregnancy and is not recommended for breastfeeding mothers, as the drug may be excreted in breast milk.

To order Methergin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The most common alternative uterotonic is oxytocin, which works via oxytocin receptors to stimulate uterine contraction. Methylergometrine, an ergot alkaloid, also activates serotonin and alpha‑adrenergic pathways, offering a stronger and longer‑lasting contraction. It is often used when oxytocin alone is insufficient or as part of combination therapy.

Methergin should be stored below 25 °C in its original packaging, protected from light and moisture. The product must be kept in a dry environment and handled with aseptic technique to maintain sterility before intramuscular, intravenous, or subcutaneous administration.

Methergin is supplied as a sterile injectable solution and may be given intramuscularly, intravenously, or subcutaneously. The route and rate of administration are selected by the treating clinician according to the clinical scenario and patient response.

Serious adverse events include severe hypertension, coronary artery spasm, pulmonary edema, uterine rupture, anaphylactic reactions, and peripheral gangrene. Patients should be monitored closely for signs of cardiovascular compromise, excessive uterine contraction, or allergic responses during and after administration.

Methergin is contraindicated in pregnant women (category X), patients with uncontrolled hypertension, coronary artery disease, peripheral vascular disease, severe hepatic or renal impairment, and those taking MAO inhibitors or other ergot alkaloids. Caution is also advised for individuals with known hypersensitivity to the drug.